An intensive three-drug regimen of heart medications did not significantly impact the rate of serious cardiovascular events at five years in women ...

The “neutral” trial, troubled by the COVID-19 pandemic, found that intensive medical therapy didn’t lower events in INOCA.

For patients with cancer requiring extended anticoagulant therapy, a strategy of reduced-dose apixaban was noninferior to full-dose apixaban for prevention of cancer-associated recurrent venous ...